TMC’S parent Unilabs cracks the ten million Covid-19 test mark

Geneva, 26 April 2021: Unilabs, the leading European diagnostic group, has hit a key milestone in its fight against Covid-19, passing the 10 million Covid-19 test mark. “Since December last year, we have doubled our Covid-19 test volumes – a remarkable achievement for our front-line teams across our seventeen countries,” said Dr Christian Rebhan, Unilabs’ Chief Medical and Operations Officer. “As the vaccines are rolled out and the world prepares to open up again, testing remains crucial to quickly identifying and containing the virus wherever it turns up.”

“Our teams have put their heart and soul into delivering this success, working tirelessly to ramp up capacity, secure supplies, take samples from our patients, and deliver accurate results as quickly as possible,” said Timóteo Guimarães, who runs Unilabs’ Covid-19 business unit. Since the outbreak of Covid-19, TMC and Unilabs have actively been doing their part in fighting the pandemic. Due to the high demand in times of Covid-19, healthcare systems have come under increasing pressure and many institutions have relied on external providers like TMC to take pressure off the overloaded system and continue to provide high-quality care.

TMC has contributed to the diagnosis of Covid-related pneumonia, and vaccine-related complications since the beginning of the pandemic. Chest radiologists also see an increasing number of radiological chest examinations of patients with long-term Covid effects, such as persistent pathological patterns in the lung tissue. Since the start of the pandemic, TMC’s parent Unilabs has hugely increased both sampling and testing capacity. Equipped with state-of-the-art technology, and with dedicated new labs in Portugal, the Netherlands, UK and the UAE, the current capacity at Unilabs exceeds 500,000 tests per week and rising.

The bulk of the tests are PCR tests. Unilabs also offers rapid antigen tests, as well as serology tests, which provide insight into the level of antibodies in a patient’s bloodstream, and thus the patients’ immune response to the virus. Demand for serology tests is rising as more people get vaccinated, since these tests can evaluate the patient’s individual reaction to the vaccine.

Unilabs has also introduced innovative new techniques and technologies to improve, speed up, and broaden testing. This includes tests that specifically identify variants such as the UK or South African variant, as well as new kinds of tests such as saliva or gargling tests.

To minimise risks for patients and staff, Unilabs has also created innovative workflows, setting up more than two hundred drive- and walk-throughs. Unilabs also carries out some Covid-19 sampling at its roughly 1,000 regular collection centres. At the same time, it has introduced dedicated zones to allow vulnerable non-Covid patients – such as the elderly and the immunosuppressed – to continue routine testing for other conditions.

Telemedicine Clinic UK joins NHS Targeted Lung Health Check programme

,

Telemedicine Clinic, in Partnership with Alliance Medical and Doncaster Clinical Commissioning Group (CCG), has started providing reporting services for low dose CT scans as part of the UK NHS’s Targeted National Lung Health Check programme.

The project in Doncaster is part of a wider UK pilot designed to improve the nation’s lung health by catching cancers at an earlier stage. Whenever appropriate, patients will be offered low dose CT scans. The report from these scans will be completed using specialist TMC chest radiologists accredited by the British Society of Thoracic Imaging.

“Finding cancer early is crucial to surviving it – the earlier the diagnosis, the better the outcome and the more chance there is for recovery,” said Gareth Davies, TMC’s UK Medical Director. “TMC are delighted to have been chosen to support this project – utilising our UK and European network of qualified specialist radiologists, and in conjunction with the best AI software, we are able to deliver a service that will literally help save lives.”

“TMC have already shown they can adapt and be flexible with the CCG in the time they’ve been on board,” said Dr Jason Page, Clinical Director for the project. “The ability to have a partner who can bring advanced Artificial intelligence at the outset of the project is a great benefit to the residents of Doncaster who will be involved in Lung Health Checks.”

The Doncaster Lung Health Check Programme and others like it across the UK are designed to rule out lung disease and to detect cancer at an earlier stage, which hugely increases the chance of survival. The reporting uses industry-leading Artificial Intelligence from Aidence. In their reporting, radiologists will use Aidence’s AI solution Veye Chest to identify and manage any suspected lung nodules.

“We are honoured to team up with one of the leading teleradiology companies in the UK and the EU in a programme which we are confident will improve people’s lives,” said Mark-Jan Harte, Aidence co-founder and CEO.